Multi-marker approach to reducing the intermediate range of a high accuracy 2-cutoff plasma p-Tau 217 test for amyloid detection

Poster

p-Tau 217 is considered the most accurate single plasma biomarker for detecting amyloid pathology. Recently, expert workgroups have recommended that p-Tau 217 tests be designed with two cut-offs in recognition of signal overlap between diseased and non-diseased subjects¹,². Two cutoffs maximize the accuracy of the test but leaves a diagnostic intermediate zone with uncertainty of amyloid status. It is desirable to minimize the indeterminant zone to reduce the number of patients receiving uncertain results. We investigated whether the inclusion of plasma amyloid beta 42/40 ratio, NfL, and GFAP into a multi-marker logistic regression model including p-Tau 217 would enable amyloid classification of uncertain results from p-Tau 217 alone. Download our poster to learn more.

[1] Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's Dement. 2024; 1-27.

[2] Schindler, S.E., Galasko, D., Pereira, A.C. et al. Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease. Nat Rev Neurol 20, 426–439 (2024).

If you see this, do not fill:

Fill in the form below.

First Name *
Last Name *
Email *
Company *
What type of organization is your company? *
Country *
State *
Therapeutic Area
To select multiple values, hold down the Shift or Control (PC) or Command (Mac) key.
I consent

By submitting this form, you agree to Quanterix’s Terms of Use and Privacy Policy. In addition, you agree to receive information regarding Quanterix products and services. You will be able to unsubscribe at any time.